The prefrontal cortex (PFC) serves as the chief executive officer of the brain, controlling the
highest level cognitive and emotional processes. Its local circuits among glutamatergic …

Stress is a primary risk factor for several neuropsychiatric disorders. Evidence from
preclinical models and clinical studies of depression have revealed an array of structural …

Depression is the leading cause of disability worldwide. Recent observations have revealed
an association between mood disorders and alterations of the intestinal microbiota. Here …

A revamped interest in the study of hallucinogens has recently emerged, especially with
regard to their potential application in the treatment of psychiatric disorders. In the last …

Depression is a common, devastating illness. Current pharmacotherapies help many
patients, but high rates of a partial response or no response, and the delayed onset of the …

Most currently available antidepressants target monoamine neurotransmitter function.
However, a purely neurotransmitter-based explanation for antidepressant drug action is …

The balance between oxidation and antioxidant is crucial for maintaining homeostasis. Once
disrupted, it can lead to various pathological outcomes and diseases, such as depression …

Psychedelics have inspired new hope for treating brain disorders, as they seem to be unlike
any treatments currently available. Not only do they produce sustained therapeutic effects …

Mounting evidence suggests safety and efficacy of psychedelic compounds as potential
novel therapeutics in psychiatry. Ketamine has been approved by the Food and Drug …

Major depressive disorder (MDD) is a leading cause of distress, disability, and suicides. As
per the latest WHO report, MDD affects more than 260 million people worldwide. Despite …